SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice

Abstract Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In clinical studies it has been shown that SGLT2i’s promote a general shift to fasting state metabolism chara...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Damilola D. Adingupu, Sven O. Göpel, Julia Grönros, Margareta Behrendt, Matus Sotak, Tasso Miliotis, Ulrika Dahlqvist, Li-Ming Gan, Ann-Cathrine Jönsson-Rylander
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2019-02-01
coleção:	Cardiovascular Diabetology
Assuntos:	Coronary Endothelial Microvascular Prediabetes SGLT2
Acesso em linha:	http://link.springer.com/article/10.1186/s12933-019-0820-6
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!